Nothing Special   »   [go: up one dir, main page]

PL3190177T3 - Bioaktywne komórki nerkowe - Google Patents

Bioaktywne komórki nerkowe

Info

Publication number
PL3190177T3
PL3190177T3 PL16196757T PL16196757T PL3190177T3 PL 3190177 T3 PL3190177 T3 PL 3190177T3 PL 16196757 T PL16196757 T PL 16196757T PL 16196757 T PL16196757 T PL 16196757T PL 3190177 T3 PL3190177 T3 PL 3190177T3
Authority
PL
Poland
Prior art keywords
renal cells
bioactive renal
bioactive
cells
renal
Prior art date
Application number
PL16196757T
Other languages
English (en)
Inventor
Roger M. Ilagan
Russell W. Keller
Sharon C. Presnell
Sumana Choudhury
Andrew T. Bruce
Christopher W. Genheimer
Bryan R. Cox
Kelly I. Guthrie
Joydeep Basu
Shay M. Wallace
Eric S. Werdin
Oluwatoyin A. Knight
Namrata D. Sangha
John W. Ludlow
Craig R. Halberstadt
Richard Payne
Neil F. Robins Jr.
Darrell Mccoy
Deepak Jain
Manuel J. Jayo
Elias A. Rivera
Thomas Spencer
Benjamin Watts
Original Assignee
Prokidney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prokidney filed Critical Prokidney
Publication of PL3190177T3 publication Critical patent/PL3190177T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0684Cells of the urinary tract or kidneys
    • C12N5/0686Kidney cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • C12N2310/141MicroRNAs, miRNAs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00Methods for the dissociation of cells, e.g. specific use of enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL16196757T 2010-05-12 2011-05-12 Bioaktywne komórki nerkowe PL3190177T3 (pl)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US33403210P 2010-05-12 2010-05-12
US35389510P 2010-06-11 2010-06-11
US37207710P 2010-08-09 2010-08-09
US37188810P 2010-08-09 2010-08-09
US37658610P 2010-08-24 2010-08-24
US38876510P 2010-10-01 2010-10-01
US41293310P 2010-11-12 2010-11-12
US41338210P 2010-11-12 2010-11-12
US201161441423P 2011-02-10 2011-02-10
US201161473111P 2011-04-07 2011-04-07
EP16196757.5A EP3190177B8 (en) 2010-05-12 2011-05-12 Bioactive renal cells
PCT/US2011/036347 WO2011143499A1 (en) 2010-05-12 2011-05-12 Bioactive renal cells
EP11722663.9A EP2569418B1 (en) 2010-05-12 2011-05-12 Bioactive renal cells

Publications (1)

Publication Number Publication Date
PL3190177T3 true PL3190177T3 (pl) 2022-06-06

Family

ID=44121234

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16196757T PL3190177T3 (pl) 2010-05-12 2011-05-12 Bioaktywne komórki nerkowe

Country Status (15)

Country Link
US (3) US10077442B2 (pl)
EP (3) EP3190177B8 (pl)
JP (6) JP5974215B2 (pl)
KR (5) KR102428776B1 (pl)
CN (2) CN106214700B (pl)
AU (5) AU2011252915B2 (pl)
CA (1) CA2798900C (pl)
DK (1) DK3190177T3 (pl)
ES (1) ES2906750T3 (pl)
HK (1) HK1232143A1 (pl)
HU (1) HUE058155T2 (pl)
NZ (1) NZ603482A (pl)
PL (1) PL3190177T3 (pl)
TW (5) TWI690320B (pl)
WO (1) WO2011143499A1 (pl)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
US20090104649A1 (en) 2007-06-11 2009-04-23 Garovic Vesna D Markers for preeclampsia
BR112012017767A2 (pt) 2009-12-21 2019-09-24 Mayo Found Medical Education & Res marcador precoce de proteinúria em pacientes tratados com um tratamento anti-vegf
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
TWI690320B (zh) 2010-05-12 2020-04-11 開曼群島商英瑞金公司 生物活性腎細胞
CA3065694A1 (en) 2010-11-10 2012-05-18 Inregen Methods of forming injectable formulations for providing regenerative effects to an organ such as a kidney
WO2013170146A1 (en) 2012-05-10 2013-11-14 Uab Research Foundation Methods and compositions for modulating mir-204 activity
EP2861238A4 (en) 2012-06-05 2016-03-16 Capricor Inc OPTIMIZED METHODS FOR GENERATING CARDIAC STEM CELLS FROM CARDIAC TISSUE AND THEIR USE IN CARDIAC THERAPY
US9828603B2 (en) 2012-08-13 2017-11-28 Cedars Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
AU2013334276B2 (en) * 2012-10-24 2019-07-04 Prokidney Renal cell populations and uses thereof
DK2994528T3 (da) * 2013-05-08 2024-02-05 Prokidney Organoider, der omfatter isolerede renale celler og anvendelser deraf
WO2015080838A1 (en) * 2013-11-27 2015-06-04 Mayo Foundation For Medical Education And Research Detecting podocyte injury in diabetic nephropathy and glomerulonephritis
CA2942384C (en) 2014-03-12 2024-01-23 Icahn School Of Medicine At Mount Sinai Method for identifying kidney allograft recipients at risk for chronic injury
EP3161165B1 (en) 2014-06-26 2020-11-18 Icahn School of Medicine at Mount Sinai Method for diagnosing subclinical and clinical acute rejection by analysis of predictive gene sets, therapeutic agent for use in the treatment and kits for determining the expression
CN106661634B (zh) 2014-06-26 2021-03-12 西奈山伊坎医学院 用于诊断肾异体移植物纤维化和排异风险的方法
CN104195107B (zh) * 2014-06-30 2017-12-15 中国人民解放军军事医学科学院野战输血研究所 微囊泡在诱导干细胞巨核分化中的用途
US11357799B2 (en) 2014-10-03 2022-06-14 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
US11180810B2 (en) 2015-09-29 2021-11-23 Research Institute At Nationwide Children's Hospital Methods for detecting hepatic fibrosis and responsiveness to therapy
US11253551B2 (en) 2016-01-11 2022-02-22 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
BR112018072797A2 (pt) 2016-05-06 2019-03-12 Unicyte Ev Ag veículos farmacêuticos contendo mirnas para uso no tratamento de doenças fibróticas causadas por hiperglicemia
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
US11123372B2 (en) 2016-07-29 2021-09-21 Prokidney Bioactive renal cells for the treatment of chronic kidney disease
EP3515459A4 (en) 2016-09-20 2020-08-05 Cedars-Sinai Medical Center CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS
KR101725025B1 (ko) * 2016-11-25 2017-04-10 서울대학교산학협력단 무형성골질환 진단용 miRNA 마커
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
WO2018195210A1 (en) 2017-04-19 2018-10-25 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
CN107236799B (zh) * 2017-06-15 2020-06-09 昆明医科大学第六附属医院 一种肾纤维化miRNA标记物
US11890395B2 (en) 2017-06-16 2024-02-06 Avery Therapeutics, Inc. Three dimensional tissue compositions and methods of use
AU2018290250A1 (en) * 2017-06-21 2019-12-19 Timothy A. Bertram Immunoprivileged bioactive renal cells for the treatment of kidney disease
CN111601890B (zh) * 2017-12-14 2024-04-19 联合细胞Ev股份公司 用于治疗肾癌的包含miRNA的药物载体
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
CA3095198A1 (en) 2018-04-16 2019-10-24 Icahn School Of Medicine At Mount Sinai Method and kits for prediction of acute rejection and renal allograft loss using pre-transplant transcriptomic signatures in recipient blood
TWI698640B (zh) * 2018-04-23 2020-07-11 長庚醫療財團法人高雄長庚紀念醫院 用於檢測狼瘡性腎炎或評估狼瘡性腎炎風險的方法及其應用
US20210386786A1 (en) * 2018-08-31 2021-12-16 Timothy A. Bertram Compositions comprising cell-delivered vesicles and uses thereof
JP2022506212A (ja) * 2018-10-29 2022-01-17 エイブリィ セラピューティクス インコーポレイテッド 改変組織の凍結保存及び再構成のための組成物及び方法
CN111733234A (zh) * 2019-03-25 2020-10-02 深圳大学 一种食管癌分子标志物及其应用
TW202122572A (zh) * 2019-08-09 2021-06-16 日商宇部興產股份有限公司 胞外體的產生方法
EP4015635A4 (en) * 2019-08-16 2023-10-25 Public University Corporation Nagoya City University MARKER FOR THE DIAGNOSIS OF COLORECTAL CARCINOMA, METHOD FOR AIDING THE DIAGNOSIS OF COLORECTAL CARCINOMA, METHOD FOR COLLECTING DATA FOR THE DIAGNOSIS OF COLORECTAL CARCINOMA, DIAGNOSTIC KIT FOR COLORECTAL CARCINOMA, THERAPEUTIC FOR COLORECTAL CARCINOMA, METHOD FOR TREATING COLORECTAL CARCINOMA AND METHOD FOR DIAGNOSING COLORECTAL CARCINOMA
CN110734972B (zh) * 2019-11-28 2023-06-16 河北仁博科技有限公司 miR-181c-3p作为肾纤维化标志物的应用
CA3174551A1 (en) 2020-03-04 2021-09-10 Metcela Inc. Fibroblast having enhanced erythropoietin production ability
CN112263587B (zh) * 2020-10-23 2022-08-30 河北仁博科技有限公司 miR-3065-5p在制备预防和/或治疗肾纤维化的药物中的应用
CN112760376B (zh) * 2020-12-30 2021-12-07 陈晓熠 miRNA-3918在非小细胞肺癌检测中的应用
WO2023107698A1 (en) * 2021-12-09 2023-06-15 Encellin, Inc. Methods and devices for pre-vascularization of implantation sites and/or cell encapsulation devices
CN116240161B (zh) * 2023-02-27 2024-05-10 四川大学华西医院 具有肾脏损伤修复作用的细胞外囊泡制备方法及应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032508A (en) 1988-09-08 1991-07-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US5863531A (en) 1986-04-18 1999-01-26 Advanced Tissue Sciences, Inc. In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework
CN1053698C (zh) 1989-01-19 2000-06-21 南京大学 细胞培养生产促红细胞生成素的方法
WO1990012604A1 (en) 1989-04-25 1990-11-01 Vacanti Joseph P Method for implanting large volumes of cells on polymeric matrices
WO1993007913A1 (en) 1991-10-24 1993-04-29 Children's Medical Center Corporation Neomorphogenesis of urological structures in vivo from cell culture
US5549674A (en) 1992-03-02 1996-08-27 The Regents Of The University Of Michigan Methods and compositions of a bioartificial kidney suitable for use in vivo or ex vivo
US6283761B1 (en) 1992-09-08 2001-09-04 Raymond Anthony Joao Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information
US6224893B1 (en) 1997-04-11 2001-05-01 Massachusetts Institute Of Technology Semi-interpenetrating or interpenetrating polymer networks for drug delivery and tissue engineering
JP2004155788A (ja) * 1998-09-24 2004-06-03 Tanabe Seiyaku Co Ltd 腎疾患治療薬およびそのスクリーニング方法
DK1180686T3 (da) 1999-05-27 2010-01-04 Cmic Co Ltd Lægemidler til nyresygdomme og fremgangsmåde til screening deraf
KR100369788B1 (ko) 1999-09-03 2003-01-29 동아제약 주식회사 재조합 인간 에리트로포이에틴의 제조방법
WO2002061053A1 (en) 2001-01-31 2002-08-08 The General Hospital Corporation Renal stem cells and uses thereof
AU2002340463A1 (en) 2001-11-16 2003-06-10 Children's Medical Center Corporation Augmentation of organ function
MXPA04009234A (es) 2002-03-22 2005-01-25 Kissei Pharmaceutical Agente preventivo o terapeutico para enfermedades renales.
JP2004309186A (ja) 2003-04-02 2004-11-04 Tokai Univ 小胞体ストレスの改善剤およびその評価方法
JP4750697B2 (ja) * 2003-06-25 2011-08-17 オタワ ヘルス リサーチ インスティテュート 幹細胞の成長及び分化を調節する方法及び組成物
WO2005059133A2 (en) * 2003-12-19 2005-06-30 Antisense Pharma Gmbh Combination therapy associating a tgf-breta antagonist with a chemiotherapeutic agent
US20070128174A1 (en) 2005-09-21 2007-06-07 Kleinsek Donald A Methods and compositions for organ and tissue functionality
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
CA3019254C (en) 2006-02-07 2021-01-19 Spinalcyte, Llc Use of chondrocyte-like cells to treat a joint in need of repair
CA2641733C (en) 2006-02-10 2015-03-31 Tengion, Inc. Scaffolds for organ reconstruction and augmentation
CA2676546A1 (en) 2006-04-24 2007-11-08 Stemcell Institute Inc. Method for preparing an organ for transplantation
WO2007127848A1 (en) * 2006-04-26 2007-11-08 University Of Louisville Research Foundation, Inc Isolation of membrane vesicles from biological fluids and methods of using same
US10500230B2 (en) 2006-10-12 2019-12-10 DePuy Synthes Products, Inc. Kidney-derived cells and methods of use in tissue repair and regeneration
ES2374954T3 (es) 2006-11-16 2012-02-23 Genentech, Inc. Variaciones genéticas asociadas con tumores.
US20110008347A1 (en) 2006-12-01 2011-01-13 Agency For Science ,Technology And Research Cancer-related protein kinases
US7924332B2 (en) * 2007-05-25 2011-04-12 The Trustees Of The University Of Pennsylvania Current/voltage mode image sensor with switchless active pixels
US10590391B2 (en) 2007-06-08 2020-03-17 Wake Forest University Health Sciences Selective cell therapy for the treatment of renal failure
EP2162529B1 (en) 2007-06-08 2019-03-27 Wake Forest University Health Sciences Selective cell therapy for the treatment of renal failure
DE102007033074A1 (de) * 2007-07-13 2009-01-15 Pac Tech-Packaging Technologies Gmbh Verfahren und Vorrichtung zur Entfernung von Lotmaterialdepots von einem Substrat
EP2211875B1 (en) 2007-10-29 2013-05-29 Fresenius Medical Care Deutschland GmbH Use of microvesicles (mvs) derived from stem cells for preparing a medicament for endo/epithelial regeneration of damaged or injured tissues or organs, and related in vitro and in vivo methods
EP2067785A1 (en) 2007-12-03 2009-06-10 Fresenius Medical Care Deutschland GmbH Human CD154-binding synthetic peptide and uses thereof
SG10201609507TA (en) 2008-02-01 2017-01-27 Gen Hospital Corp Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
EP2186883A1 (en) 2008-11-04 2010-05-19 Fresenius Medical Care An isolated multipotent mesenchymal stem cell from human adult glomeruli (hGL-MSC), a method of preparing thereof and uses thereof in the regenerative medicine of the kidney
US8318484B2 (en) 2008-11-12 2012-11-27 Tengion, Inc. Isolated renal cells and uses thereof
WO2010057015A1 (en) 2008-11-14 2010-05-20 Wake Forest University Health Sciences Kidney structures and methods of forming the same
JP5565607B2 (ja) 2009-07-15 2014-08-06 国立大学法人 東京大学 敗血症又は多臓器不全の予後診断方法及び予後診断用キット
EP2333047A1 (en) 2009-12-09 2011-06-15 Fresenius Medical Care Deutschland GmbH Adult stem cell derived conditioned medium and/or adult stem cells for use in the therapeutic treatment of a tumor disease
EP2363136A1 (en) 2010-03-02 2011-09-07 Fresenius Medical Care Deutschland GmbH Microvesicles (MVs) derived from adult stem cells for use in the therapeutic treatment of a tumor disease
TWI690320B (zh) 2010-05-12 2020-04-11 開曼群島商英瑞金公司 生物活性腎細胞
CA3065694A1 (en) 2010-11-10 2012-05-18 Inregen Methods of forming injectable formulations for providing regenerative effects to an organ such as a kidney
CN111635883A (zh) 2013-12-16 2020-09-08 弗雷森纽斯医疗护理德国有限责任公司 胰岛样细胞结构及其制备方法
WO2017178472A1 (en) 2016-04-12 2017-10-19 Unicyte Ev Ag Isolation of extracellular vesicles (evs) from biological fluid samples
BR112018072797A2 (pt) 2016-05-06 2019-03-12 Unicyte Ev Ag veículos farmacêuticos contendo mirnas para uso no tratamento de doenças fibróticas causadas por hiperglicemia

Also Published As

Publication number Publication date
KR20130064753A (ko) 2013-06-18
CA2798900A1 (en) 2011-11-17
AU2016216646B2 (en) 2017-11-09
JP2018203746A (ja) 2018-12-27
JP2020201266A (ja) 2020-12-17
AU2016216646A1 (en) 2016-09-01
AU2018200761A1 (en) 2018-02-22
JP7442852B2 (ja) 2024-03-05
AU2020203727B2 (en) 2023-02-02
KR20210024686A (ko) 2021-03-05
EP2569418B1 (en) 2016-11-02
US10077442B2 (en) 2018-09-18
AU2020203727A1 (en) 2020-06-25
CN103154236A (zh) 2013-06-12
TW202027762A (zh) 2020-08-01
AU2011252915A1 (en) 2012-11-29
KR102428776B1 (ko) 2022-08-04
US11066666B2 (en) 2021-07-20
TWI542690B (zh) 2016-07-21
TW202228737A (zh) 2022-08-01
TWI629990B (zh) 2018-07-21
EP3190177A1 (en) 2017-07-12
CN106214700B (zh) 2021-09-07
KR102539589B1 (ko) 2023-06-01
KR101975212B1 (ko) 2019-05-07
KR20180027604A (ko) 2018-03-14
JP6744368B2 (ja) 2020-08-19
EP2569418A1 (en) 2013-03-20
JP6385976B2 (ja) 2018-09-05
TW201902494A (zh) 2019-01-16
HUE058155T2 (hu) 2022-07-28
EP4083191A1 (en) 2022-11-02
KR20220112863A (ko) 2022-08-11
TW201700106A (zh) 2017-01-01
JP2024056860A (ja) 2024-04-23
DK3190177T3 (da) 2022-01-31
US20210238600A1 (en) 2021-08-05
CN106214700A (zh) 2016-12-14
AU2011252915B2 (en) 2016-05-19
CA2798900C (en) 2021-10-12
KR20190047141A (ko) 2019-05-07
WO2011143499A1 (en) 2011-11-17
TWI762890B (zh) 2022-05-01
CN103154236B (zh) 2016-08-31
US20160244751A1 (en) 2016-08-25
JP2016208963A (ja) 2016-12-15
TWI690320B (zh) 2020-04-11
US20180282726A1 (en) 2018-10-04
KR101834830B1 (ko) 2018-04-19
TWI840787B (zh) 2024-05-01
JP2013528375A (ja) 2013-07-11
JP5974215B2 (ja) 2016-08-24
TW201211255A (en) 2012-03-16
NZ603482A (en) 2014-11-28
KR102223564B1 (ko) 2021-03-05
JP2022153631A (ja) 2022-10-12
AU2023202707A1 (en) 2023-05-18
EP3190177B8 (en) 2022-07-27
EP3190177B1 (en) 2022-01-12
ES2906750T3 (es) 2022-04-20
HK1232143A1 (zh) 2018-01-05
JP7123426B2 (ja) 2022-08-23
NZ796266A (en) 2024-04-26

Similar Documents

Publication Publication Date Title
HK1232143A1 (zh) 生物活性腎細胞
EP2600904A4 (en) ARTIFICIAL CELLS
GB201017019D0 (en) Cell selection
EP2614439A4 (en) STORAGE SYSTEM
EP2612246A4 (en) STORAGE SYSTEM
EP2612231A4 (en) STORAGE SYSTEM
GB201006488D0 (en) Battery
GB201113558D0 (en) Kraftfahrzeugkarosserie mit strukturverstarkter vorderrahmenanbindung
GB201000375D0 (en) T Cell clonotypes
EP2612245A4 (en) STORAGE SYSTEM
GB201116180D0 (en) Kraftfahrzeug mit warnsystem
EP2619102A4 (en) NETWORK CONTAINER SYSTEM
GB201017421D0 (en) Cell
EP2546916A4 (en) BATTERY
EP2659540A4 (en) BATTERY
EP2589098A4 (en) ACCUMULATOR
EP2610940A4 (en) BATTERY RACK
GB201009998D0 (en) Cell disruption
EP2535065A4 (en) dialyzer
GB2476879B (en) Swimmer-propulsion units
EP2654096A4 (en) BATTERY
EP2600441A4 (en) COATED CELL
GB201018480D0 (en) Factors
TWM389358U (en) Battery
GB201016852D0 (en) Cell differentiation